Hepion Pharmaceuticals Inc (HEPA) - Total Liabilities
Based on the latest financial reports, Hepion Pharmaceuticals Inc (HEPA) has total liabilities worth $402.40K USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hepion Pharmaceuticals Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Hepion Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Hepion Pharmaceuticals Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Hepion Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Hepion Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Conduit Capital Ltd
JSE:CND
|
South Africa | ZAC1.52 Billion |
|
FINTECH S.A. ZY 5
F:9DZ
|
Germany | €16.20 Million |
|
Ravelin Properties REIT
TO:RPR-UN
|
Canada | CA$1.22 Billion |
|
Crown Place VCT PLC
LSE:CRWN
|
UK | GBX1.17 Million |
|
Alps Industries Limited
NSE:ALPSINDUS
|
India | Rs9.37 Billion |
|
Konsortium AG
MU:KUB1
|
Germany | €8.56 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Hepion Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Hepion Pharmaceuticals Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hepion Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hepion Pharmaceuticals Inc (2012–2025)
The table below shows the annual total liabilities of Hepion Pharmaceuticals Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $402.40K | -88.43% |
| 2024-12-31 | $3.48 Million | -67.85% |
| 2023-12-31 | $10.81 Million | +4.09% |
| 2022-12-31 | $10.39 Million | -1.60% |
| 2021-12-31 | $10.56 Million | +29.93% |
| 2020-12-31 | $8.12 Million | +62.66% |
| 2019-12-31 | $4.99 Million | -19.62% |
| 2018-12-31 | $6.21 Million | -17.69% |
| 2017-12-31 | $7.55 Million | -35.96% |
| 2016-12-31 | $11.79 Million | +508.28% |
| 2015-12-31 | $1.94 Million | -60.72% |
| 2014-12-31 | $4.93 Million | 0.00% |
| 2013-12-31 | $4.93 Million | +2071.59% |
| 2012-12-31 | $227.21K | -- |
About Hepion Pharmaceuticals Inc
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as … Read more